X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (31724) 31724
Book Review (5255) 5255
Publication (1027) 1027
Newsletter (443) 443
Book Chapter (153) 153
Newspaper Article (122) 122
Magazine Article (109) 109
Conference Proceeding (65) 65
Dissertation (23) 23
Book / eBook (14) 14
Trade Publication Article (12) 12
Government Document (7) 7
Reference (4) 4
Data Set (3) 3
Paper (3) 3
Web Resource (3) 3
Transcript (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (26835) 26835
humans (23635) 23635
male (12519) 12519
female (12108) 12108
heparin (10621) 10621
heparin - administration & dosage (9436) 9436
middle aged (8109) 8109
aged (6638) 6638
animals (6371) 6371
adult (6296) 6296
heparin - therapeutic use (5876) 5876
anticoagulants - administration & dosage (5568) 5568
abridged index medicus (5234) 5234
anticoagulants - therapeutic use (4983) 4983
anticoagulants (4249) 4249
molecular-weight heparin (4081) 4081
hematology (4032) 4032
peripheral vascular disease (3895) 3895
heparin - adverse effects (3434) 3434
surgery (3423) 3423
treatment outcome (3386) 3386
heparin - pharmacology (3168) 3168
thrombosis (3162) 3162
cardiac & cardiovascular systems (3102) 3102
anticoagulants - adverse effects (3092) 3092
risk factors (3090) 3090
time factors (2795) 2795
unfractionated heparin (2303) 2303
prevention (2288) 2288
heparin, low-molecular-weight - administration & dosage (2236) 2236
thromboembolism (2211) 2211
pharmacology & pharmacy (2189) 2189
venous thromboembolism (2176) 2176
heparin, low-molecular-weight - therapeutic use (2148) 2148
rats (2132) 2132
prospective studies (2009) 2009
dose-response relationship, drug (1928) 1928
aged, 80 and over (1901) 1901
deep-vein thrombosis (1872) 1872
medicine, general & internal (1836) 1836
therapy (1803) 1803
fibrinolytic agents - therapeutic use (1764) 1764
retrospective studies (1753) 1753
anticoagulation (1744) 1744
pregnancy (1694) 1694
drug therapy (1678) 1678
care and treatment (1615) 1615
postoperative complications - prevention & control (1590) 1590
blood coagulation - drug effects (1545) 1545
enoxaparin (1496) 1496
thromboembolism - prevention & control (1490) 1490
thrombocytopenia - chemically induced (1488) 1488
hemorrhage - chemically induced (1477) 1477
analysis (1469) 1469
fibrinolytic agents - administration & dosage (1466) 1466
drug therapy, combination (1450) 1450
thrombosis - prevention & control (1420) 1420
adolescent (1419) 1419
glycosaminoglycans (1411) 1411
cardiopulmonary bypass (1375) 1375
injections, subcutaneous (1374) 1374
medicine & public health (1374) 1374
health aspects (1365) 1365
research (1356) 1356
mice (1340) 1340
partial thromboplastin time (1322) 1322
anticoagulants - pharmacology (1301) 1301
risk (1269) 1269
warfarin (1254) 1254
dosage and administration (1240) 1240
venous thrombosis (1232) 1232
drug administration schedule (1205) 1205
administration, oral (1202) 1202
management (1192) 1192
follow-up studies (1145) 1145
heparin-induced thrombocytopenia (1121) 1121
thrombolytic therapy (1120) 1120
injections, intravenous (1095) 1095
infusions, intravenous (1093) 1093
pulmonary embolism (1071) 1071
prophylaxis (1057) 1057
heparin, low-molecular-weight - adverse effects (1050) 1050
venous thrombosis - prevention & control (1036) 1036
coagulation (1032) 1032
thrombosis - drug therapy (1030) 1030
venous thrombosis - drug therapy (1026) 1026
myocardial infarction - drug therapy (1016) 1016
aspirin (1008) 1008
respiratory system (998) 998
complications (997) 997
pulmonary-embolism (993) 993
recurrence (986) 986
thrombin (986) 986
blood coagulation tests (966) 966
diagnosis (944) 944
cancer (938) 938
acute disease (924) 924
mortality (923) 923
low molecular weight heparin (908) 908
rabbits (905) 905
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (28904) 28904
German (1085) 1085
French (668) 668
Russian (599) 599
Japanese (318) 318
Spanish (204) 204
Italian (178) 178
Polish (136) 136
Chinese (80) 80
Czech (53) 53
Hungarian (49) 49
Danish (43) 43
Portuguese (40) 40
Swedish (32) 32
Dutch (31) 31
Norwegian (31) 31
Bulgarian (23) 23
Korean (16) 16
Romanian (15) 15
Croatian (9) 9
Serbian (9) 9
Finnish (8) 8
Ukrainian (8) 8
Hebrew (7) 7
Turkish (6) 6
Lithuanian (5) 5
Slovak (4) 4
Persian (2) 2
Afrikaans (1) 1
Arabic (1) 1
Bosnian (1) 1
Icelandic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The Lancet, ISSN 0140-6736, 08/2001, Volume 358, Issue 9282, pp. 605 - 613
Current fibrinolytic therapies fail to achieve optimum reperfusion in many patients. Low-molecular-weight heparins and platelet glycoprotein IIb/IIIa... 
MEDICINE, GENERAL & INTERNAL | THROMBOLYSIS | Recurrence | Humans | Middle Aged | Heparin - administration & dosage | Male | Tissue Plasminogen Activator - administration & dosage | Treatment Outcome | Chi-Square Distribution | Enoxaparin - administration & dosage | Immunoglobulin Fab Fragments - administration & dosage | Injections | Myocardial Infarction - drug therapy | Antibodies, Monoclonal - administration & dosage | Platelet Aggregation Inhibitors - administration & dosage | Survival Analysis | Female | Aged | Fibrinolytic Agents - administration & dosage | Drug Therapy, Combination | Dosage and administration | Thrombolytic drugs | Research | Tenecteplase | Drug therapy | Heart attack | Prevention | Evaluation | Ischemia | Enoxaparin | Reperfusion (Physiology) | Drug therapy, Combination | Heparin | Health aspects | Clinical trials | Heart attacks | Myocardial infarction | Coagulation | Hemorrhage | Bleeding | Infusion | Randomization | Reperfusion | Motivation | Blood platelets | Safety | Heparins | Anticoagulants | Stroke | Effectiveness | Complications | Mortality | Glycoprotein | Pharmacology | Patients | Trauma | Molecular chains | Studies | Fibrin | Monoclonal antibodies | Infarction | Index Medicus | Abridged Index Medicus | Heparin/administration & dosage | Medical and Health Sciences | Medicin och hälsovetenskap | Platelet Aggregation Inhibitors/administration & dosage | MEDICINE | Antibodies; Monoclonal/administration & dosage | Myocardial Infarction/drug therapy | Enoxaparin/administration & dosage | Tissue Plasminogen Activator/administration & dosage | Fibrinolytic Agents/administration & dosage | MEDICIN | Immunoglobulins; Fab/administration & dosage | Drug Therapy; Combination | Research Support; Non-U.S. Gov't
Journal Article
European Heart Journal, ISSN 0195-668X, 2014, Volume 35, Issue 34, pp. 2285 - 2294
Journal Article
Circulation, ISSN 0009-7322, 07/2011, Volume 124, Issue 3, pp. 304 - 313
Journal Article
Lancet, The, ISSN 0140-6736, 2008, Volume 372, Issue 9632, pp. 31 - 39
Summary Background The risk of venous thromboembolism is high after total hip arthroplasty and could persist after hospital discharge. Our aim was to compare... 
Internal Medicine | WEIGHT HEPARIN-PROPHYLAXIS | MEDICINE, GENERAL & INTERNAL | PLACEBO | FACTOR-XA INHIBITOR | ORTHOPEDIC-SURGERY | KNEE REPLACEMENT | BAY-59-7939 | THROMBOSIS | PROLONGED THROMBOPROPHYLAXIS | TIME-COURSE | DALTEPARIN | Thiophenes - therapeutic use | Double-Blind Method | Drug Administration Schedule | Thiophenes - adverse effects | Humans | Middle Aged | Morpholines - administration & dosage | Arthroplasty, Replacement, Hip | Male | Thiophenes - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Fibrinolytic Agents - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Fibrinolytic Agents - administration & dosage | Morpholines - adverse effects | Morpholines - therapeutic use | Health care | Medical imaging | Hospitals | Protease inhibitors | Surgery | Tomography | Joint surgery | Drug therapy | Patients | Veins & arteries | Index Medicus | Abridged Index Medicus | Thiophenes/administration & dosage/adverse effects/therapeutic use | use | Arthroplasty | Replacement | Venous Thromboembolism/prevention & control | Morpholines/administration & dosage/adverse effects/therapeutic use | Kirurgi | Hip | 80 and over | Enoxaparin/administration & dosage/adverse effects/therapeutic use | Fibrinolytic Agents/administration & dosage/adverse effects/therapeutic
Journal Article
by Schulman, Sam and Kakkar, Ajay K and Goldhaber, Samuel Z and Schellong, Sebastian and Eriksson, Henry and Mismetti, Patrick and Christiansen, Anita Vedel and Friedman, Jeffrey and Le Maulf, Florence and Peter, Nuala and Kearon, Clive and Schulman, S and Eriksson, H and Goldhaber, S and Kakkar, A and Kearon, C and Mismetti, P and Schellong, S and Bergqvist, D and Tijssen, J and Prins, M. [=Martin H.] and Robben, S and Büller, H and Otten, H. M and Brandjes, D and Peters, R and Mac Gillavry, M. R and Gan, E and Salem, H and Baker, R and Blomberry, P and Curnow, J and Annichino-Bizzacch, J. M and Brandao Panico, M. D and Timi Ribas, J. R and Fernandes Manenti, E. R and Miranda, F and Moraes, J and Raev, D and Mollov, M and Peneva, M and Milanov, S and Anderson, D and Crowther, M and Dolan, S and Eikelboom, J and Game, M and Kahn, S and Kassis, J and Ritchie, B and Solymoss, S and Rodger, M and Yeo, E and Milot, A and Klinke, P and Chen, W and Zhihong, L and Chunxue, B and Jinming, L and Jiwei, Z and Jie, C and Jina, K and Yuqi, W and Zhongqi, Y and Hua, W and Kejing, Y and Bonan, L and Yadong, Y and Changwei, L and Jin, Z and Yongcheng, D and Spinar, J and Maly, R and Cizek, V and Bercikova, J and Cervinka, P and Lang, P and Jirka, V and Oral, I and Reichert, P and Kotik, L and Pojsl, S and Klimovic, T and Husted, S and Nielsen, H and Friis, E and Skødebjerg Kristensen, K and Mottier, D and El Kouri, D and Bleher, Y and Leroux, L and Boda, Z and Sereg, M and Riba, M and Hiremath, J. S and Kareem, S and Banker, D. N and Gadkari, M and Parakh, R and Suresh, K. R and ... and RE-COVER II Trial Investigators
Circulation, ISSN 0009-7322, 2014, Volume 129, Issue 7, pp. 764 - 772
Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those... 
Antagonists & inhibitors | Recurrence | Thrombin | Warfarin | Hemorrhage | Venous thromboembolism | CARDIAC & CARDIOVASCULAR SYSTEMS | FONDAPARINUX | THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | RIVAROXABAN | INITIAL TREATMENT | PERIPHERAL VASCULAR DISEASE | ORAL ANTICOAGULANT-THERAPY | APIXABAN | UNFRACTIONATED HEPARIN | Anticoagulants - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Warfarin - adverse effects | Male | Antithrombins - administration & dosage | Dabigatran | Heparin - adverse effects | Warfarin - administration & dosage | Venous Thromboembolism - drug therapy | Young Adult | Benzimidazoles - administration & dosage | Adult | Female | Benzimidazoles - adverse effects | Venous Thromboembolism - epidemiology | beta-Alanine - analogs & derivatives | Acute Disease | beta-Alanine - adverse effects | Double-Blind Method | Hemorrhage - epidemiology | Risk Factors | beta-Alanine - administration & dosage | Anticoagulants - adverse effects | Antithrombins - adverse effects | Adolescent | Aged | Hemorrhage - chemically induced | Heparin, Low-Molecular-Weight - administration & dosage | Usage | Care and treatment | Dabigatran etexilate | Thromboembolism | Index Medicus | Abridged Index Medicus | Anticoagulants | Benzimidazoles | Heparin, Low-Molecular-Weight | Life Sciences | Venous Thromboembolism | Antithrombins | Heparin | beta-Alanine
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 01/2009, Volume 101, Issue 1, pp. 77 - 85
Dabigatran etexilate has been investigated in three phase III trials for the prevention of venous thromboembolism (VTE). Health technology assessment agencies... 
anticoagulants | thrombosis | prophylaxis | Embolism | Meta-analysis | Anticoagulants | Thrombosis | Prophylaxis | ENOXAPARIN | meta-analysis | RANDOMIZED-TRIAL | REPLACEMENT | ORTHOPEDIC-SURGERY | MOLECULAR-WEIGHT HEPARIN | THROMBOSIS PROPHYLAXIS | US HOSPITALS | PERIPHERAL VASCULAR DISEASE | THROMBOPROPHYLAXIS | HEMATOLOGY | UNFRACTIONATED HEPARIN | REGISTRY | Venous Thromboembolism - mortality | Anticoagulants - administration & dosage | Arthroplasty, Replacement, Knee - adverse effects | Humans | Dabigatran | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - prevention & control | Clinical Trials, Phase III as Topic | Enoxaparin - administration & dosage | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Pyridines - administration & dosage | Drug Administration Schedule | Risk Assessment | Administration, Oral | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Arthroplasty, Replacement, Hip - adverse effects | Venous Thromboembolism - etiology | Hemorrhage - chemically induced | Index Medicus | Administration | Phase III as Topic | Benzimidazoles/administration & dosage/adverse effects/therapeutic use | Pyridines/administration & dosage/adverse effects/therapeutic use | Arthroplasty | Replacement | Oral | Clinical Trials | Kirurgi | Knee/adverse effects | Hemorrhage/chemically induced | Venous Thromboembolism/etiology/mortality/prevention & control | Hip/adverse effects | Anticoagulants/administration & dosage/adverse effects/therapeutic use | Surgery | Enoxaparin/administration & dosage/adverse effects/therapeutic use
Journal Article
Journal Article
Journal Article
JAMA, ISSN 0098-7484, 02/2005, Volume 293, Issue 6, pp. 681 - 689
CONTEXT Ximelagatran, an oral direct thrombin inhibitor with a rapid onset of action and predictable antithrombotic effect, has the potential to be a simple... 
ORAL XIMELAGATRAN | ENOXAPARIN | MEDICINE, GENERAL & INTERNAL | KNEE REPLACEMENT | THERAPY | VENOUS THROMBOEMBOLISM | MELAGATRAN | INTRAVENOUS UNFRACTIONATED HEPARIN | ABSORPTION | INHIBITOR XIMELAGATRAN | SECONDARY PREVENTION | Prodrugs - administration & dosage | Recurrence | Anticoagulants - administration & dosage | Humans | Middle Aged | Male | Venous Thrombosis - complications | Heparin, Low-Molecular-Weight - therapeutic use | Warfarin - administration & dosage | Warfarin - therapeutic use | Aged, 80 and over | Adult | Female | Drug Therapy, Combination | Pulmonary Embolism - complications | Double-Blind Method | Venous Thrombosis - drug therapy | Venous Thrombosis - mortality | Anticoagulants - therapeutic use | Treatment Outcome | Azetidines - administration & dosage | Azetidines - therapeutic use | Benzylamines | Aged | Prodrugs - therapeutic use | Alanine Transaminase - metabolism | Heparin, Low-Molecular-Weight - administration & dosage | Clinical trials | Cardiac arrhythmia | Thrombolytic drugs | Medical treatment | Blood clots | Index Medicus | Abridged Index Medicus | Low-Molecular-Weight/administration & dosage/therapeutic use | Anticoagulants/administration & dosage/therapeutic use | Pulmonary Embolism/complications | Drug Therapy | MEDICIN OCH HÄLSOVETENSKAP | Alanine Transaminase/metabolism | Warfarin/administration & dosage/therapeutic use | 80 and over | Azetidines/administration & dosage/therapeutic use | Combination | Prodrugs/administration & dosage/therapeutic use | Venous Thrombosis/complications/drug therapy/mortality | Heparin | MEDICAL AND HEALTH SCIENCES
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 04/2011, Volume 105, Issue 4, pp. 721 - 729
This trial compared the efficacy and safety of oral dabigatran, a direct thrombin inhibitor, versus subcutaneous enoxaparin for extended thromboprophylaxis in... 
Dabigatran etexilate | Oral anticoagulant | Total hip arthroplasty | Venous thromboembolism | Prophylaxis | SURGERY | DIRECT THROMBIN INHIBITOR | FONDAPARINUX | oral anticoagulant | PREVENTION | DEEP-VEIN THROMBOSIS | prophylaxis | total hip arthroplasty | KNEE REPLACEMENT | venous thromboembolism | MOLECULAR-WEIGHT HEPARIN | ETEXILATE | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | Venous Thromboembolism - mortality | Anticoagulants - administration & dosage | Humans | Middle Aged | Male | Antithrombins - administration & dosage | Dabigatran | Enoxaparin - adverse effects | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Benzimidazoles - administration & dosage | Hemorrhage - etiology | Injections, Subcutaneous | Female | Venous Thrombosis - prevention & control | Benzimidazoles - adverse effects | beta-Alanine - analogs & derivatives | Postoperative Complications | beta-Alanine - adverse effects | Double-Blind Method | Administration, Oral | Venous Thrombosis - mortality | beta-Alanine - administration & dosage | Anticoagulants - adverse effects | Venous Thrombosis - etiology | Venous Thromboembolism - etiology | Antithrombins - adverse effects | Survival Analysis | Arthroplasty, Replacement, Hip - mortality | Aged | Benzimidazoles | Venous Thrombosis | Oral | Hemorrhage | Antithrombins | Venous Thromboembolism | administration & dosage | Surgery | beta-Alanine | Administration | Anticoagulants | Subcutaneous | Enoxaparin | Arthroplasty | Replacement | prevention & control | Kirurgi | Hip | etiology | Injections | analogs & derivatives | adverse effects | mortality
Journal Article